In the ever-changing behavioral health care industry, providers are constantly challenged by shifting payer landscapes, regulatory hurdles, and public scrutiny. For American Addiction Centers (AAC), the past several years have been particularly turbulent. Financial headwinds, leadership changes, and insurance challenges forced the company into a defensive posture, consolidating resources just to stay afloat.
Now, under the leadership of CEO Andrew McWilliams, AAC is preparing to flip the script. The company, which operates dozens of facilities across eight states, is embracing a new offensive strategy for 2020 and beyond. This shift aims to restore stability, expand innovation, and refocus on AAC’s clinical mission—providing quality treatment to individuals battling substance use disorders.
A Difficult Few Years
AAC, the parent company of American Addiction Centers, has been one of the largest names in addiction treatment. But size has not shielded it from difficulties. In 2019, the company endured executive departures, including its president, COO, and multiple board members. That same year, AAC was delisted from the New York Stock Exchange after failing to meet minimum market capitalization thresholds.
On top of internal challenges, AAC and other providers in the behavioral health care field faced payer restrictions that made it harder for patients to access treatment. Insurance pre-authorization requirements, shorter lengths of stay approvals, and outright denials of coverage created financial strain for organizations and uncertainty for patients in need.
Despite these challenges, AAC’s leadership began laying the groundwork for a turnaround. According to McWilliams, the second half of 2019 showed signs of improvement. By consolidating beds in certain markets such as Nevada, Florida, and Southern California, the company managed to better align its operations with the new reimbursement environment. While these moves reduced costs, AAC made it a priority to avoid compromising the quality of its clinical care.
Leadership Transition
In January 2020, McWilliams officially stepped into the CEO role. Having joined AAC in 2014 as chief accounting officer and later serving as CFO, he brought institutional knowledge and a strong financial background to the position.
Michael Cartwright, who had long served as both CEO and chairman, transitioned fully into his chairman role. This leadership restructuring allowed AAC to clearly divide responsibilities, enabling McWilliams to focus on operational strategy while Cartwright concentrated on governance and long-term vision.
McWilliams described his move into the top leadership position as both challenging and exciting. “There are easier paths than this,” he admitted, but his passion for the addiction treatment field and his belief in AAC’s mission motivated him to take on the challenge.
The Payer Landscape
One of AAC’s most significant hurdles remains the payer environment. Insurance companies, McWilliams explained, have grown increasingly aggressive with prior authorizations and denials. While payers argue these steps control costs, providers contend they create barriers to care—particularly harmful during an ongoing opioid crisis.
AAC has responded by increasing charity care, often providing treatment at no cost when insurers deny coverage. While this decision creates financial strain, it reflects AAC’s commitment to patient care and safety. McWilliams believes the industry needs stronger advocacy and more open dialogue with payers to resolve these systemic issues.
A New Offensive Strategy
With the defensive measures of 2018 and 2019 behind them, AAC is positioning itself for growth and innovation in 2020. McWilliams has outlined a clear offensive strategy that includes:
- Investing in Clinical Excellence – AAC has prioritized maintaining high-quality clinical staff and services, even while reducing operating costs elsewhere. The company has resisted cutting clinical staff-to-patient ratios, ensuring patients receive attentive, evidence-based care.
- Harnessing Technology – AAC has adopted innovative tools to improve care delivery. For example, EarlySense technology is used in detox facilities to monitor patient vitals unobtrusively during sleep, reducing risks and improving patient comfort. Additionally, diagnostic testing, including pharmacogenetics, is helping clinicians create more personalized treatment plans with fewer trial-and-error adjustments.
- Exploring Telehealth Solutions – Recognizing shifting patient needs and younger demographics, AAC is embracing telehealth. Virtual care options allow for expanded access, particularly important for aftercare and outpatient support.
- Advancing a Long-Term Vision – AAC’s 10-year plan emphasizes individualized care supported by cutting-edge diagnostics and technology. The goal is not just to improve outcomes but to create scalable models that could set new standards of care in addiction treatment.
Industry Context
AAC’s strategy unfolds against a backdrop of industry-wide changes. The Trump administration’s FY 2021 budget proposal, released earlier this year, included significant funding for addiction treatment, particularly for medication-assisted treatment (MAT). While McWilliams supports increased funding, he cautions against oversimplifying addiction by focusing solely on MAT. He stresses the importance of integrating MAT with comprehensive clinical services for long-term success.
The addiction treatment field is also seeing increased consolidation, with smaller providers either closing or being absorbed by larger players. McWilliams anticipates more stability in the market moving forward, as insurers and providers adapt to new norms. This stability, he believes, will allow AAC and others to focus on improving clinical services rather than simply surviving.
Opportunities and Challenges Ahead
While AAC is optimistic about 2020, challenges remain. The company must continue to navigate payer pressures, manage its financial footing, and rebuild trust with investors after its delisting. Still, McWilliams is confident in AAC’s direction.
He emphasizes that AAC’s size gives it unique advantages, allowing the organization to invest in technologies and care innovations smaller providers cannot. This scale, coupled with a passionate workforce, positions AAC to help set industry standards and advocate for the future of addiction treatment.
Looking Forward
McWilliams views 2020 as a turning point, marking a shift from defense to offense. The company’s renewed focus on clinical excellence, technology integration, and individualized care represents a bold strategy to strengthen its role as an industry leader.
While the road ahead is not without obstacles, AAC’s leadership believes stability is returning to the behavioral health care field. If the company can successfully implement its offensive strategy, it may not only secure its own future but also help shape the broader addiction treatment landscape.
AAC’s story is one of resilience. After years of setbacks, the organization is pushing forward with new leadership, a clear plan, and a renewed commitment to patients. As McWilliams puts it, the passion of AAC’s employees and the needs of patients remain the driving force behind the company’s efforts: “We’ve been playing defense for the past year and a half to two years. This year, we’ll get back to a little bit more offense.”
